SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-047480
Filing Date
2021-09-09
Accepted
2021-09-09 16:16:06
Documents
43
Period of Report
2021-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-10q_20210731.htm   iXBRL 10-Q 1139293
2 EX-31.1 kalv-ex311_8.htm EX-31.1 24695
3 EX-31.2 kalv-ex312_6.htm EX-31.2 23013
4 EX-32.1 kalv-ex321_7.htm EX-32.1 9536
  Complete submission text file 0001564590-21-047480.txt   3990531

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA kalv-20210731.xsd EX-101.SCH 24497
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20210731_cal.xml EX-101.CAL 44030
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20210731_def.xml EX-101.DEF 43208
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20210731_lab.xml EX-101.LAB 199791
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20210731_pre.xml EX-101.PRE 139534
10 EXTRACTED XBRL INSTANCE DOCUMENT kalv-10q_20210731_htm.xml XML 703953
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 211244585
SIC: 2834 Pharmaceutical Preparations